Related stories
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?
Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?
Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?
A Tax Strategy So Aggressive It Built the World’s Largest Hedge Fund and Made Losing Money the Hottest Product on Wall Street
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?
The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.